Key clinical point: Extending treatment with adjuvant anastrozole to 10 years improves disease free survival and distant DFS in HR+ breast cancer.
Major finding: DFS was 91.9% in patients who continued anastrozole versus 84.4% in those who stopped anastrozole after the initial 5 years (hazard ratio, 0.548; P = .0004).
Study details: A prospective, randomized, open-label, phase 3 study of 1,683 patients.
Disclosures: Dr. Ohtani has received speaker fees from CHUGAI, Astra Zeneca, Novartis, and Ezai.
Ohtani S et al. SABCS 2018, Abstract GS3-04.
This Week's Must Reads
Haplo-HCT shows viability in DLBCL, Dreger P et al. Blood Adv. 2019 Feb 12;3(3):360-9
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.
Inadequate emergency care a challenge for rural pediatric patients, Walling EB et al. J Oncol Pract. 2019 Jan 31. doi: 10.1200/JOP.18.00115.
QC measures improve with CMS Oncology Care Model, Rocque G et al. J Oncol Pract. 2019. doi: 10. 1200/JOP.18.00390.
Women less likely to receive industry funds, Weng JK et al. JAMA Netw Open. 2019 Jan. 25. doi: 10.1001/jamanetworkopen.2018.7377.
Must Reads in Breast Cancer
Therapeutic drug monitoring for tamoxifen not justified, Sanchez-Spitman A et al. J Clin Oncol. 2019 Jan 24. doi: 10.1200/JCO.18.00307.
With a positive sentinel node, RT better than surgery, Rutgers EJT et al. SABCS 2018, Abstract GS4-01
Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04
Outcomes better in TNBC with adjuvant chemotherapy within 30 days of surgery, Morante Z et al., SABCS 2018 Abstract GS2-05
Advanced age not linked with risk from nipple-sparing mastectomy, Cox S et al. and Bartholomew AJ et al. Session SF310 ACS Clinical Congress 2018